Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma

Next Previous
Trial Profile

A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2-hydroxyoleic acid (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Laminar Pharmaceuticals

Most Recent Events

  • 13 Jul 2021 Status changed from recruiting to completed.
  • 27 Mar 2020 According to a Laminar Pharma company website, Lipopharma has changed its name to Laminar Pharma.
  • 27 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top